The Biomarker Discovery Laboratory in the Clinical Chemistry Service identifies new biomarkers that have potential clinical utility in managing patients with cancer. This translational laboratory specializes in validating new assays for clinical use. These assays include the enrichment of circulating tumor cells (CTC) from peripheral blood and body fluids in patients with metastatic cancer, genomic analysis of CTC to identify upregulated genes that are targets for new therapeutic agents, development of multiplex assays that have the potential of disease risk assessment, and the validation of new technology for CTC analysis and exosome analysis in patients with cancer.
Preferred Project Dates
Students are expected to be in attendance all eight weeks, start and end dates inclusive.